Structural and Functional Basis for the Long QT Syndrome: Relevance to Veterinary Patients

Journal of Veterinary Internal Medicine

Volumn 17, Issue 4, 2003, Pages 473-488

  Finley, Melissa R ^a,c   Lillich, James D ^a   Gilmour Jr , Robert F ^b   Freeman, Lisa C ^a  

^a KANSAS STATE UNIVERSITY   (United States)

^b Department of Obstetrics Gynecology   (United States)

^c SALK INSTITUTE FOR BIOLOGICAL STUDIES   (United States)

Author keywords

Cardiac repolarization; Ether a go go related; IKr; KCNH channels; Torsades de pointes

Indexed keywords

AMIODARONE; AMITRIPTYLINE; ANESTHETIC AGENT; ANTIARRHYTHMIC AGENT; ANTIHISTAMINIC AGENT; ANTIINFECTIVE AGENT; ASTEMIZOLE; AZIMILIDE; CARVEDILOL; CHLORPHENIRAMINE; CIPROFLOXACIN; CISAPRIDE; CLARITHROMYCIN; CLEMASTINE; CLINDAMYCIN; CLOMIPRAMINE; DIPHENHYDRAMINE; DISOPYRAMIDE; DOFETILIDE; DOMPERIDONE; DOXEPIN; DROPERIDOL; ERYTHROMYCIN; IMIPRAMINE; LORATADINE; METOCLOPRAMIDE; PROKINETIC AGENT; PSYCHOTROPIC AGENT; QUINIDINE; SOTALOL; VETERINARY DRUG;

DISEASE ASSOCIATION; DRUG APPROVAL; ECG ABNORMALITY; ELECTROLYTE BALANCE; GENDER; GENE MUTATION; GENETIC CODE; HEART ELECTROPHYSIOLOGY; HEART MUSCLE POTENTIAL; HEART RATE; HEART REPOLARIZATION; HEART VENTRICLE ARRHYTHMIA; HORSE; HUMAN; HYPOKALEMIA; ION CHANNEL; LONG QT SYNDROME; NONHUMAN; PHARMACOLOGICAL BLOCKING; POTASSIUM CURRENT; QT INTERVAL; REVIEW; RISK FACTOR; VETERINARY MEDICINE; ANIMAL; ANIMAL DISEASE; CHEMICALLY INDUCED DISORDER; PATHOPHYSIOLOGY;

ANIMALIA; EQUUS CABALLUS;

ANIMALS; HUMANS; LONG QT SYNDROME; VETERINARY DRUGS;

EID: 0041382967     PISSN: 08916640     EISSN: None     Source Type: Journal    
DOI: 10.1892/0891-6640(2003)017<0473:SAFBFT>2.3.CO;2     Document Type: Review

References (234)

1. Moss AJ, Schwartz PJ, Crampton RS, et al. The long QT syndrome. Prospective longitudinal study of 328 families. Circulation 1991;84:1136-1144.
2. Reef VB, Reimer JM, Spencer PA. Treatment of atrial fibrillation in horses: New perspectives. J Vet Intern Med 1995;9:57-67.
3. Dumaine R, Antzelevitch C. Molecular mechanisms underlying the long QT syndrome. Curr Opin Cardiol 2002;17:36-42.
4. Towbin JA, Vatta M. Molecular biology and the prolonged QT syndromes. Am J Med 2001;110:385-398.
5. Bennett PB. Long QT syndrome: Biophysical and pharmacologic mechanisms in LQT3. J Cardiovasc Electrophysiol 2000;11:819-822.
6. January CT, Gong Q, Zhou Z. Long QT syndrome: Cellular basis and arrhythmia mechanism in LQT2. J Cardiovasc Electrophysiol 2000;11:1413-1418.
7. Sanguinetti MC. Dysfunction of delayed rectifier potassium channels in an inherited arrhythmia. Ann N Y Acad Sci 1999;868: 406-413.
8. Sanguinetti MC. Long QT syndrome: Ionic basis and arrhythmia mechanism in long QT syndrome type 1. J Cardiovasc Electrophysiol 2000;11:710-712.
9. Haverkamp W, Breithardt G, Camm AJ, et al. The potential for QT prolongation and pro-arrhythmia by non-anti-arrhythmic drugs: Clinical and regulatory implications. Report on a Policy Conference of the European Society of Cardiology. Cardiovasc Res 2000;47:219-233.
10. Nattel S. Acquired delayed rectifier channelopathies: How heart disease and antiarrhythmic drugs mimic potentially lethal congenital cardiac disorders. Cardiovasc Res 2000;48:188-190.
11. Roden DM, Lazzara R, Rosen M, et al. Multiple mechanisms in the long-QT syndrome. Current knowledge, gaps, and future directions. The SADS Foundation Task Force on LQTS. Circulation 1996; 94:1996-2012.
12. Campbell DL, Rasmusson RL, Qu Y, Strauss HC. The calcium-independent transient outward potassium current in isolated ferret right ventricular myocytes. I. Basic characterization and kinetic analysis. J Gen Physiol 1993;101:571-601.
13. Litovsky SH, Antzelevitch C. Transient outward current prominent in canine ventricular epicardium but not endocardium. Circ Res 1988;62:116-126.
14. Maylie J, Morad M. A transient outward current related to calcium release and development of tension in elephant seal atrial fibres. J Physiol 1984;357:267-292.
15. Pacioretty LM, Gilmour RF Jr. Developmental changes of action potential configuration and I(to) in canine epicardium. Am J Physiol 1995;268:H2513-H2521.
16. Schackow TE, Decker RS, Ten Eick RE. Electrophysiology of adult cat cardiac ventricular myocytes: Changes during primary culture. Am J Physiol 1995;268:C1002-C1017.
17. Furukawa T, Myerburg RJ, Furukawa N, et al. Differences in transient outward currents of feline endocardial and epicardial myocytes. Circ Res 1990;67:1287-1291.
18. Nerbonne JM, Nichols CG, Schwarz TL, Escande D. Genetic manipulation of cardiac K(+) channel function in mice: What have we learned, and where do we go from here? Circ Res 2001;89:944-956.
19. Tseng GN, Hoffman BF. Two components of transient outward current in canine ventricular myocytes. Circ Res 1989;64:633-647.
20. Zygmunt AC, Gibbons WR. Calcium-activated chloride current in rabbit ventricular myocytes. Circ Res 1991;68:424-437.
21. Antzelevitch C. Molecular basis for the transmural distribution of the transient outward current. J Physiol 2001;533:1.
22. Yan GX, Antzelevitch C. Cellular basis for the electrocardiographic J wave. Circulation 1996;93:372-379.
23. Hoppe UC, Marban E, Johns DC. Molecular dissection of cardiac repolarization by in vivo Kv4.3 gene transfer. J Clin Invest 2000; 105:1077-1084.
24. Zygmunt AC, Eddlestone GT, Thomas GP, et al. Larger late sodium conductance in M cells contributes to electrical heterogeneity in canine ventricle. Am J Physiol Heart Circ Physiol 2001;281:H689-H697.
25. Barajas-Martinez H, Elizalde A, Sanchez-Chapula JA. Developmental differences in delayed rectifying outward current in feline ventricular myocytes. Am J Physiol Heart Circ Physiol 2000;278: H484-H492.
26. Follmer CH, Colatsky TJ. Block of delayed rectifier potassium current, IK, by flecainide and E-4031 in cat ventricular myocytes. Circulation 1990;82:289-293.
27. Gintant GA. Two components of delayed rectifier current in canine atrium and ventricle. Does IKs play a role in the reverse rate dependence of class III agents? Circ Res 1996;78:26-37.
28. Li GR, Feng J, Yue L, et al. Evidence for two components of delayed rectifier K+ current in human ventricular myocytes. Circ Res 1996;78:689-696.
29. Liu DW, Antzelevitch C. Characteristics of the delayed rectifier current (IKr and IKs) in canine ventricular epicardial, midmyocardial, and endocardial myocytes. A weaker IKs contributes to the longer action potential of the M cell. Circ Res 1995;76:351-365.
30. Salata JJ, Jurkiewicz NK, Jow B, et al. IK of rabbit ventricle is composed of two currents: Evidence for IKs. Am J Physiol 1996; 271:H2477-H2489.
31. Sanguinetti MC, Jurkiewicz NK. Two components of cardiac delayed rectifier K+ current. Differential sensitivity to block by class III antiarrhythmic agents. J Gen Physiol 1990;96:195-215.
32. Shibasaki T. Conductance and kinetics of delayed rectifier potassium channels in nodal cells of the rabbit heart. J Physiol 1987; 387:227-250.
33. Tseng GN. I(Kr): The hERG channel. J Mol Cell Cardiol 2001; 33:835-849.
34. Burashnikov A, Antzelevitch C. Prominent I(Ks) in epicardium and endocardium contributes to development of transmural dispersion of repolarization but protects against development of early afterdepolarizations. J Cardiovasc Electrophysiol 2002;13:172-177.
35. Viswanathan PC, Shaw RM, Rudy Y. Effects of IKr and IKs heterogeneity on action potential duration and its rate dependence: A simulation study. Circulation 1999;99:2466-2474.
36. Nattel S, Yue L, Wang Z. Cardiac ultrarapid delayed rectifiers: A novel potassium current family of functional similarity and molecular diversity. Cell Physiol Biochem 1999;9:217-226.
37. Furukawa T, Kimura S, Furukawa N, et al. Potassium rectifier currents differ in myocytes of endocardial and epicardial origin. Circ Res 1992;70:91-103.
38. Liu DW, Gintant GA, Antzelevitch C. Ionic bases for electrophysiological distinctions among epicardial, midmyocardial, and endocardial myocytes from the free wall of the canine left ventricle. Circ Res 1993;72:671-687.
39. January CT, Moscucci A. Cellular mechanisms of early afterdepolarizations. Ann N Y Acad Sci 1992;644:23-32.
40. Volders PG, Vos MA, Szabo B, et al. Progress in the understanding of cardiac early afterdepolarizations and torsades de pointes: Time to revise current concepts. Cardiovasc Res 2000;46:376-392.
41. Shieh CC, Coghlan M, Sullivan JP, Gopalakrishnan M. Potassium channels: Molecular defects, diseases, and therapeutic opportunities. Pharmacol Rev 2000;52:557-594.
42. Snyders DJ. Structure and function of cardiac potassium channels. Cardiovasc Res 1999;42:377-390.
43. Bezzina CR, Rook MB, Wilde AA. Cardiac sodium channel and inherited arrhythmia syndromes. Cardiovasc Res 2001;49:257-271.
44. Balser JR. Inherited sodium channelopathies: Novel therapeutic and proarrhythmic molecular mechanisms. Trends Cardiovasc Med 2001;11:229-237.
45. Balser JR. Inherited sodium channelopathies: Models for acquired arrhythmias? Am J Physiol Heart Circ Physiol 2002;282: H1175-H1180.
46. Freeman LC, Pacioretty LM, Moise NS, et al. Decreased density of Ito in left ventricular myocytes from German shepherd dogs with inherited arrhythmias. J Cardiovasc Electrophysiol 1997;8:872-883.
47. Plaster NM, Tawil R, Tristani-Firouzi M, et al. Mutations in Kir2.1 cause the developmental and episodic electrical phenotypes of Andersen's syndrome. Cell 2001;105:511-519.
48. Abbott GW, Goldstein SA. Disease-associated mutations in KCNE potassium channel subunits (MiRPs) reveal promiscuous disruption of multiple currents and conservation of mechanism. FASEB J 2002;16:390-400.
49. Sanguinetti MC. Maximal function of minimal K+ channel subunits. Trends Pharmacol Sci 2000;21:199-201.
50. Weerapura M, Nattel S, Chartier D, et al. A comparison of currents carried by HERG, with and without coexpression of MiRP1, and the native rapid delayed rectifier current. Is MiRP1 the missing link? J Physiol 2002;540:15-27.
51. Roden DM. Pharmacogenetics and drug-induced arrhythmias. Cardiovasc Res 2001;50:224-231.
52. Hiraoka M, Sawada K, Kawano S. Effects of quinidine on plateau currents of guinea-pig ventricular myocytes. J Mol Cell Cardiol 1986;18:1097-1106.
53. Imaizumi Y, Giles WR. Quinidine-induced inhibition of transient outward current in cardiac muscle. Am J Physiol 1987;253: H704-H708.
54. Lee KS, Hume JR, Giles W, Brown AM. Sodium current depression by lidocaine and quinidine in isolated ventricular cells. Nature 1981;291:325-327.
55. Po SS, Wang DW, Yang IC, et al. Modulation of HERG potassium channels by extracellular magnesium and quinidine. J Cardiovasc Pharmacol 1999;33:181-185.
56. Yao JA, Trybulski EJ, Tseng GN. Quinidine preferentially blocks the slow delayed rectifier potassium channel in the rested state. J Pharmacol Exp Ther 1996;279:856-864.
57. Yang T, Roden DM. Extracellular potassium modulation of drug block of IKr. Implications for torsades de pointes and reverse use-dependence. Circulation 1996;93:407-411.
58. Snyders J, Knoth KM, Roberds SL, Tamkun MM. Time-, voltage-, and state-dependent block by quinidine of a cloned human cardiac potassium channel. Mol Pharmacol 1992;41:322-330.
59. Bauman JL, Bauernfeind RA, Hoff JV, et al. Torsades de pointes due to quinidine: Observations in 31 patients. Am Heart J 1984;107:425-430.
60. Roden DM, Thompson KA, Hoffman BF, Woosley RL. Clinical features and basic mechanisms of quinidine-induced arrhythmias. J Am Coll Cardiol 1986;8:73A-78A.
61. Roden DM, Woosley RL, Primm RK. Incidence and clinical features of the quinidine-associated long QT syndrome: Implications for patient care. Am Heart J 1986;111:1088-1093.
62. Thompson KA, Murray JJ, Blair IA, et al. Plasma concentrations of quinidine, its major metabolites, and dihydroquinidine in patients with torsades de pointes. Clin Pharmacol Ther 1988;43:636-642.
63. Jurkiewicz NK, Sanguinetti MC. Rate-dependent prolongation of cardiac action potentials by a methanesulfonanilide class III anti-arrhythmic agent. Specific block of rapidly activating delayed rectifier K+ current by dofetilide. Circ Res 1993;72:75-83.
64. Vandenberg JI, Walker BD, Campbell TJ. HERG K+ channels: Friend and foe. Trends Pharmacol Sci 2001;22:240-246.
65. Woosley RL, Chen Y, Freiman JP, Gillis RA. Mechanism of the cardiotoxic actions of terfenadine. JAMA 1993;269:1532-1536.
66. Wysowski DK, Corken A, Gallo-Torres H, et al. Postmarketing reports of QT prolongation and ventricular arrhythmia in association with cisapride and Food and Drug Administration regulatory actions. Am J Gastroenterol 2001;96:1698-1703.
67. Hondeghem LM, Snyders DJ. Class III antiarrhythmic agents have a lot of potential but a long way to go. Reduced effectiveness and dangers of reverse use dependence. Circulation 1990;81:686-690.
68. Benton RE, Sale M, Flockhart DA, Woosley RL. Greater quinidine-induced QTc interval prolongation in women. Clin Pharmacol Ther 2000;67:413-418.
69. Drici MD, Burklow TR, Haridasse V, et al. Sex hormones prolong the QT interval and downregulate potassium channel expression in the rabbit heart. Circulation 1996;94:1471-1474.
70. Drici MD, Knollmann BC, Wang WX, Woosley RL. Cardiac actions of erythromycin: Influence of female sex. JAMA 1998;280: 1774-1776.
71. Locati EH, Zareba W, Moss AJ, et al. Age-and sex-related differences in clinical manifestations in patients with congenital long-QT syndrome: Findings from the International LQTS Registry. Circulation 1998;97:2237-2244.
72. Pham TV, Sosunov EA, Gainullin RZ, et al. Impact of sex and gonadal steroids on prolongation of ventricular repolarization and arrhythmias induced by I(K)-blocking drugs. Circulation 2001;103: 2207-2212.
73. Rodriguez I, Kilborn MJ, Liu XK, et al. Drug-induced QT prolongation in women during the menstrual cycle. JAMA 2001;285: 1322-1326.
74. Sesti F, Abbott GW, Wei J, et al. A common polymorphism associated with antibiotic-induced cardiac arrhythmia. Proc Natl Acad Sci U S A 2000;97:10613-10618.
75. Splawski I, Shen J, Timothy KW, et al. Spectrum of mutations in long-QT syndrome genes. KVLQT1, HERG, SCN5A, KCNE1, and KCNE2. Circulation 2000;102:1178-1185.
76. Iwasa H, Kurabayashi M, Nagai R, et al. Multiple single-nucleotide polymorphisms (SNPs) in the Japanese population in six candidate genes for long QT syndrome. J Hum Genet 2001;46:158-162.
77. Hondeghem LM, Carlsson L, Duker G. Instability and triangulation of the action potential predict serious proarrhythmia, but action potential duration prolongation is antiarrhythmic. Circulation 2001;103:2004-2013.
78. Sanguinetti MC, Jurkiewicz NK. Role of external Ca2+ and K+ in gating of cardiac delayed rectifier K+ currents. Pflugers Arch 1992;420:180-186.
79. Sanguinetti MC, Jiang C, Curran ME, Keating MT. A mechanistic link between an inherited and an acquired cardiac arrhythmia: HERG encodes the IKr potassium channel. Cell 1995;81:299-307.
80. Yang T, Snyders DJ, Roden DM. Rapid inactivation determines the rectification and [K+]o dependence of the rapid component of the delayed rectifier K+ current in cardiac cells. Circ Res 1997;80:782-789.
81. Compton SJ, Lux RL, Ramsey MR, et al. Genetically defined therapy of inherited long-QT syndrome. Correction of abnormal repolarization by potassium. Circulation 1996;94:1018-1022.
82. Tan HL, Alings M, Van Olden RW, Wilde AA. Long-term (sub-acute) potassium treatment in congenital HERG-related long QT syndrome (LQTS2). J Cardiovasc Electrophysiol 1999;10:229-233.
83. Berthet M, Denjoy I, Donger C, et al. C-terminal HERG mutations: The role of hypokalemia and a KCNQ1-associated mutation in cardiac event occurrence. Circulation 1999;99:1464-1470.
84. Kubota T, Shimizu W, Kamakura S, Horie M. Hypokalemia-induced long QT syndrome with an underlying novel missense mutation in S4-S5 linker of KCNQ1. J Cardiovasc Electrophysiol 2000; 11:1048-1054.
85. Ebert SN, Liu XK, Woosley RL. Female gender as a risk factor for drug-induced cardiac arrhythmias: Evaluation of clinical and experimental evidence. J Womens Health 1998;7:547-557.
86. Pratt CM, Camm AJ, Cooper W, et al. Mortality in the survival with oral D-sotalol (SWORD) trial: Why did patients die? Am J Cardiol 1998;81:869-876.
87. Kligfield P, Lax KG, Okin PM. QT interval-heart rate relation during exercise in normal men and women: Definition by linear regression analysis. J Am Coll Cardiol 1996;28:1547-1555.
88. Rautaharju PM, Zhou SH, Wong S, et al. Sex differences in the evolution of the electrocardiographic QT interval with age. Can J Cardiol 1992;8:690-695.
89. Bidoggia H, Maciel JP, Capalozza N, et al. Sex differences on the electrocardiographic pattern of cardiac repolarization: Possible role of testosterone. Am Heart J 2000;140:678-683.
90. Shuba YM, Degtiar VE, Osipenko VN, et al. Testosterone-mediated modulation of HERG blockade by proarrhythmic agents. Biochem Pharmacol 2001;62:41-49.
91. Liu XK, Katchman A, Drici MD, et al. Gender difference in the cycle length-dependent QT and potassium currents in rabbits. J Pharmacol Exp Ther 1998;285:672-679.
92. Liu XK, Wang W, Ebert SN, et al. Female gender is a risk factor for torsades de pointes in an in vitro animal model. J Cardiovasc Pharmacol 1999;34:287-294.
93. Lu HR, Remeysen P, Somers K, et al. Female gender is a risk factor for drug-induced long QT and cardiac arrhythmias in an in vivo rabbit model. J Cardiovasc Electrophysiol 2001;12:538-545.
94. Pham TV, Rosen MR. Sex, hormones, and repolarization. Cardiovasc Res 2002;53:740-751.
95. Trepanier-Boulay V, St Michel C, Tremblay A, Fiset C. Gender-based differences in cardiac repolarization in mouse ventricle. Circ Res 2001;89:437-444.
96. Wu Y, Anderson ME. Reduced repolarization reserve in ventricular myocytes from female mice. Cardiovasc Res 2002;53:763-769.
97. Pham TV, Robinson RB, Danilo P, Rosen MR. Effects of gonadal steroids on gender-related differences in transmural dispersion of L-type calcium current. Cardiovasc Res 2002;53:752-762.
98. Gerring EL, King JN, Edwards GB, et al. A multicentre trial of cisapride in the prophylaxis of equine postoperative ileus. Equine Vet Educ 1991;3:143-145.
99. Hall JA, Washabau RJ. Diagnosis and treatment of gastric motility disorders. Vet Clin North Am Small Anim Pract 1999;29:377-395.
100. Moses L, Harpster NK, Beck KA, Hartzband L. Esophageal motility dysfunction in cats: A study of 44 cases. J Am Anim Hosp Assoc 2000;36:309-312.
101. Yang T, Snyders D, Roden DM. Drug block of I(kr): Model systems and relevance to human arrhythmias. J Cardiovasc Pharmacol 2001;38:737-744.
102. Brahmajothi MV, Morales MJ, Reimer KA, Strauss HC. Regional localization of ERG, the channel protein responsible for the rapid component of the delayed rectifier, K+ current in the ferret heart. Circ Res 1997;81:128-135.
103. Carmeliet E. Voltage-and time-dependent block of the delayed K+ current in cardiac myocytes by dofetilide. J Pharmacol Exp Ther 1992;262:809-817.
104. Nurmi A, Vornanen M. Electrophysiological properties of rainbow trout cardiac myocytes in serum-free primary culture. Am J Physiol Regul Integr Comp Physiol 2002;282:R1200-R1209.
105. Wang L, Feng ZP, Kondo CS, et al. Developmental changes in the delayed rectifier K+ channels in mouse heart. Circ Res 1996; 79:79-85.
106. Lu HR, Marien R, Saels A, De Clerck F. Species plays an important role in drug-induced prolongation of action potential duration and early afterdepolarizations in isolated Purkinje fibers. J Cardiovasc Electrophysiol 2001;12:93-102.
107. Emori T, Antzelevitch C. Cellular basis for complex T waves and arrhythmic activity following combined I(Kr) and I(Ks) block. J Cardiovasc Electrophysiol 2001;12:1369-1378.
108. Finley MR, Li Y, Hua F, et al. Expression and co-association of ERG1, KCNQ1 and KCNE1 potassium channel proteins in horse heart. Am J Physiol Heart Circ Physiol 2002;283:H126-H138.
109. Chezalviel-Guilbert F, Weissenburger J, Davy JM, et al. Proarrhythmic effects of a quinidine analog in dogs with chronic A-V block. Fundam Clin Pharmacol 1995;9:240-247.
110. Davis AS. The pre-clinical assessment of QT interval prolongation: A comparison of in vitro and in vivo methods. Hum Exp Toxicol 1998;17:677-680.
111. Drici MD, Wang WX, Liu XK, et al. Prolongation of QT interval in isolated feline hearts by antipsychotic drugs. J Clin Psychopharmacol 1998;18:477-481.
112. Satoh Y, Sugiyama A, Chiba K, et al. QT-prolonging effects of sparfloxacin, a fluoroquinolone antibiotic, assessed in the in vivo canine model with monophasic action potential monitoring. J Cardiovasc Pharmacol 2000;36:510-515.
113. Satoh Y, Sugiyama A, Tamura K, Hashimoto K. Effects of mexiletine on the canine cardiovascular system complicating cisapride overdose: Potential utility of mexiletine for the treatment of drug-induced long QT syndrome. Jpn J Pharmacol 2000;83:327-334.
114. Satoh Y, Sugiyama A, Tamura K, Hashimoto K. Effect of magnesium sulfate on the haloperidol-induced QT prolongation assessed in the canine in vivo model under the monitoring of monophasic action potential. Jpn Circ J 2000;64:445-451.
115. Sugiyama A, Hashimoto K. Effects of gastrointestinal prokinetic agents, TKS159 and cisapride, on the in situ canine heart assessed by cardiohemodynamic and electrophysiological monitoring. Toxicol Appl Pharmacol 1998;152:261-269.
116. Wang WX, Ebert SN, Liu XK, et al. "Conventional" antihistamines slow cardiac repolarization in isolated perfused (Langendorff) feline hearts. J Cardiovasc Pharmacol 1998;32:123-128.
117. Weissenburger J, Davy JM, Chezalviel F. Experimental models of torsades de pointes. Fundam Clin Pharmacol 1993;7:29-38.
118. Weissenburger J, Noyer M, Cheymol G, Jaillon P. Electrophysiological effects of cetirizine, astemizole and D-sotalol in a canine model of long QT syndrome. Clin Exp Allergy 1999;29(Suppl 3):190-196.
119. Sgarbossa EB, Pinski SL, Williams D, et al. Comparison of QT intervals in African-Americans versus Caucasians. Am J Cardiol 2000;86:880-882.
120. Chapman N, Mayet J, Ozkor M, et al. Ethnic and gender differences in electrocardiographic QT length and QT dispersion in hypertensive subjects. J Hum Hypertens 2000;14:403-405.
121. Mansi IA, Nash IS. Ethnic differences in electrocardiographic intervals and axes. J Electrocardiol 2001;34:303-307.
122. Sugiyam A, Ishida Y, Satoh Y, et al. Electrophysiological, anatomical and histological remodeling of the heart to AV block enhances susceptibility to arrhythmogenic effects of QT-prolonging drugs. Jpn J Pharmacol 2002;88:341-350.
123. Weissenburger J, Davy JM, Chezalviel E et al. Arrhythmogenic activities of antiarrhythmic drugs in conscious hypokalemic dogs with atrioventricular block: Comparison between quinidine, lidocaine, flecainide, propranolol and sotalol. J Pharmacol Exp Ther 1991;259: 871-883.
124. Kii Y, Nakatsuji K, Nose I, et al. Effects of 5-HT(4) receptor agonists, cisapride and mosapride citrate on electrocardiogram in anaesthetized rats and guinea-pigs and conscious cats. Pharmacol Toxicol 2001;89:96-103.
125. Potet F, Bouyssou T, Escande D, Baro I. Gastrointestinal prokinetic drugs have different affinity for the human cardiac human ether-a-gogo K(+) channel. J Pharmacol Exp Ther 2001;299:1007-1012.
126. Ohki R, Takahashi M, Mizuno O, et al. Torsades de pointes ventricular tachycardia induced by mosapride and flecainide in the presence of hypokalemia. Pacing Clin Electrophysiol 2001;24:119-121.
127. King JN, Gerring EL. Actions of the novel gastrointestinal prokinetic agent cisapride on equine bowel motility. J Vet Pharmacol Ther 1988;11:314-321.
128. Vitola J, Vukanovic J, Roden DM. Cisapride-induced torsades de pointes. J Cardiovasc Electrophysiol 1998;9:1109-1113.
129. Hammond TG, Carlsson L, Davis AS, et al. Methods of collecting and evaluating non-clinical cardiac electrophysiology data in the pharmaceutical industry: Results of an international survey. Cardiovasc Res 2001;49:741-750.
130. Netzer R, Ebneth A, Bischoff U, Pongs O. Screening lead compounds for QT interval prolongation. Drug Discov Today 2001;6: 78-84.
131. Riccio ML, Moise NS, Otani NF, et al. Vector quantization of T wave abnormalities associated with a predisposition to ventricular arrhythmias and sudden death. Ann Nonivas Electrocardiol 1998;3:46-53.
132. Wakefield ID, Pollard C, Redfern WS, et al. The application of in vitro methods to safety pharmacology. Fundam Clin Pharmacol 2002;16:209-218.
133. Boyle NG, Weiss JN. Making QT correction simple is complicated. J Cardiovasc Electrophysiol 2001;12:421-423.
134. Raunig D, Depasquale MJ, Huang CH, et al. Statistical analysis of QT interval as a function of changes in RR interval in the conscious dog. J Pharmacol Toxicol Methods 2001;46:1-11.
135. Malik M. Problems of heart rate correction in assessment of drug-induced QT interval prolongation. J Cardiovasc Electrophysiol 2001;12:411-420.
136. Malik M. The imprecision in heart rate correction may lead to artificial observations of drug induced QT interval changes. Pacing Clin Electrophysiol 2002;25:209-216.
137. Spier AW, Meurs KM, Muir WW, et al. Correlation of QT dispersion with indices used to evaluate the severity of familial ventricular arrhythmias in Boxers. Am J Vet Res 2001;62:1481-1485.
138. Ware WA, Christensen WF. Duration of the QT interval in healthy cats. Am J Vet Res 1999;60:1426-1429.
139. Strickland KN. QT dispersion. Proceedings American College of Veterinary Internal Medicine, Dallas, TX, 2002.
140. Burnes JE, Ghanem RN, Waldo AL, Rudy Y. Imaging dispersion of myocardial repolarization. I. Comparison of body-surface and epicardial measures. Circulation 2001;104:1299-1305.
141. Keating MT, Sanguinetti MC. Molecular and cellular mechanisms of cardiac arrhythmias. Cell 2001;104:569-580.
142. Schwartz PJ. Another role for the sympathetic nervous system in the long QT syndrome? J Cardiovasc Electrophysiol 2001;12:500-502.
143. Moise NS. Long term monitoring of animal models of sudden death. J Cardiovasc Electrophysiol 2000;11:1342-1344.
144. Apkon M, Nerbonne JM. Characterization of two distinct depolarization-activated K+ currents in isolated adult rat ventricular myocytes. J Gen Physiol 1991;97:973-1011.
145. Fiset C, Clark RB, Larsen TS, Giles WR. A rapidly activating sustained K+ current modulates repolarization and excitation-contraction coupling in adult mouse ventricle. J Physiol 1997;504(Pt 3):557-563.
146. Himmel HM, Wettwer E, Li Q, Ravens U. Four different components contribute to outward current in rat ventricular myocytes. Am J Physiol 1999;277:H107-H118.
147. Baskin EP, Lynch JJ Jr. Differential atrial versus ventricular activities of class III potassium channel blockers. J Pharmacol Exp Ther 1998;285:135-142.
148. Brahmajothi MV, Campbell DL, Rasmusson RL, et al. Distinct transient outward potassium current (Ito) phenotypes and distribution of fast-inactivating potassium channel alpha subunits in ferret left ventricular myocytes. J Gen Physiol 1999;113:581-600.
149. Potreau D, Gomez JP, Fares N. Depressed transient outward current in single hypertrophied cardiomyocytes isolated from the right ventricle of ferret heart. Cardiovasc Res 1995;30:440-448.
150. Giles WR, Imaizumi Y. Comparison of potassium currents in rabbit atrial and ventricular cells. J Physiol 1988;405:123-145.
151. Cordeiro JM, Spitzer KW, Giles WR. Repolarizing K+ currents in rabbit heart Purkinje cells. J Physiol 1998;508(Pt 3):811-823.
152. Backx PH, Marban E. Background potassium current active during the plateau of the action potential in guinea pig ventricular myocytes. Circ Res 1993;72:890-900.
153. Arena JP, Kass RS. Block of heart potassium channels by clofilium and its tertiary analogs: Relationship between drug structure and type of channel blocked. Mol Pharmacol 1988;34:60-66.
154. Sun ZQ, Thomas GP, Antzelevitch C. Chromanol 293B inhibits slowly activating delayed rectifier and transient outward currents in canine left ventricular myocytes. J Cardiovasc Electrophysiol 2001;12: 472-478.
155. Volders PG, Sipido KR, Carmeliet E, et al. Repolarizing K+ currents ITO1 and IKs are larger in right than left canine ventricular midmyocardium. Circulation 1999;99:206-210.
156. Kleiman RB, Houser SR. Outward currents in normal and hypertrophied feline ventricular myocytes. Am J Physiol 1989;256: H1450-H1461.
157. Magyar J, lost N, Kortvely A, et al. Effects of endothelin-1 on calcium and potassium currents in undiseased human ventricular myocytes. Pflugers Arch 2000;441:144-149.
158. Varro A, Nanasi PP, Lathrop DA. Potassium currents in isolated human atrial and ventricular cardiocytes. Acta Physiol Scand 1993;149:133-142.
159. Virag L, lost N, Opincariu M, et al. The slow component of the delayed rectifier potassium current in undiseased human ventricular myocytes. Cardiovasc Res 2001;49:790-797.
160. Clancy CE, Rudy Y. Cellular consequences of HERG mutations in the long QT syndrome: Precursors to sudden cardiac death. Cardiovasc Res 2001;50:301-313.
161. Barhanin J, Lesage F, Guillemare E, et al. K(V)LQT1 and IsK (minK) proteins associate to form the I(Ks) cardiac potassium current. Nature 1996;384:78-80.
162. Curran ME, Splawski I, Timothy KW, et al. A molecular basis for cardiac arrhythmia: HERG mutations cause long QT syndrome. Cell 1995;80:795-803.
163. Dixon JE, Shi W, Wang HS, et al. Role of the Kv4.3 K+ channel in ventricular muscle. A molecular correlate for the transient outward current. Circ Res 1996;79:659-668.
164. Sanguinetti MC, Curran ME, Zou A, et al. Coassembly of K(V)LQT1 and minK (IsK) proteins to form cardiac I(Ks) potassium channel. Nature 1996;384:80-83.
165. Wang Z, Fermini B, Nattel S. Sustained depolarization-induced outward current in human atrial myocytes. Evidence for a novel delayed rectifier K+ current similar to Kv1.5 cloned channel currents. Circ Res 1993;73:1061-1076.
166. Wang Z, Feng J, Shi H, et al. Potential molecular basis of different physiological properties of the transient outward K+ current in rabbit and human atrial myocytes. Circ Res 1999;19;84:551-561.
167. Wickenden AD, Jegla TJ, Kaprielian R, Backx PH. Regional contributions of Kv1.4, Kv4.2, and Kv4.3 to transient outward K+ current in rat ventricle. Am J Physiol 1999;276:H1599-H1607.
168. Xu H, Guo W, Nerbonne JM. Four kinetically distinct depolarization- activated K+ currents in adult mouse ventricular myocytes. J Gen Physiol 1999;113:661-678.
169. Yue L, Feng J, Li GR, Nattel S. Characterization of an ultrarapid delayed rectifier potassium channel involved in canine atrial repolarization. J Physiol 1996;496(Pt 3):647-662.
170. Yue L, Wang Z, Rindt H, Nattel S. Molecular evidence for a role of Shaw (Kv3) potassium channel subunits in potassium currents of dog atrium. J Physiol 2000;527(Pt 3):467-478.
171. Roden DM. Acquired long QT syndromes and the risk of proarrhythmia. J Cardiovasc Electrophysiol 2000;11:938-940.
172. Karle CA, Kreye VA, Thomas D, et al. Antiarrhythmic drug carvedilol inhibits HERG potassium channels. Cardiovasc Res 2001; 49:361-370.
173. Choudhury L, Grais IM, Passman RS. Torsades de pointes due to drug interaction between disopyramide and clarithromycin. Heart Dis 1999;1:206-207.
174. Hayashi Y, Ikeda U, Hashimoto T, et al. Torsades de pointes ventricular tachycardia induced by clarithromycin and disopyramide in the presence of hypokalemia. Pacing Clin Electrophysiol 1999;22: 672-674.
175. Wang DW, Kiyosue T, Sato T, Arita M. Comparison of the effects of class I anti-arrhythmic drugs, cibenzoline, mexiletine and flecainide, on the delayed rectifier K+ current of guinea-pig ventricular myocytes. J Mol Cell Cardiol 1996;28:893-903.
176. Salata JJ, Jurkiewicz NK, Wallace AA, et al. Cardiac electrophysiological actions of the histamine H1-receptor antagonists astemizole and terfenadine compared with chlorpheniramine and pyrilamine. Circ Res 1995;76:110-119.
177. Khalifa M, Drolet B, Daleau P, et al. Block of potassium currents in guinea pig ventricular myocytes and lengthening of cardiac repolarization in man by the histamine H1 receptor antagonist diphenhydramine. J Pharmacol Exp Ther 1999;288:858-865.
178. Zareba W, Moss AJ, Rosero SZ, et al. Electrocardiographic findings in patients with diphenhydramine overdose. Am J Cardiol 1997;80:1168-1173.
179. Crumb WJ Jr. Loratadine blockade of K(+) channels in human heart: Comparison with terfenadine under physiological conditions. J Pharmacol Exp Ther 2000;292:261-264.
180. Kang J, Wang L, Chen XL, et al. Interactions of a series of fluoroquinolone antibacterial drugs with the human cardiac K+ channel HERG. Mol Pharmacol 2001;59:122-126.
181. Patmore L, Fraser S, Mair D, Templeton A. Effects of sparfloxacin, grepafloxacin, moxifloxacin, and ciprofloxacin on cardiac action potential duration. Eur J Pharmacol 2000;406:449-452.
182. Frothingham R. Rates of torsades de pointes associated with ciprofloxacin, ofloxacin, levofloxacin, gatifloxacin, and moxifloxacin. Pharmacotherapy 2001;21:1468-1472.
183. Piquette RK. Torsades de pointes induced by cisapride/clarith-romycin interaction. Ann Pharmacother 1999;33:22-26.
184. Gabel A, Schymik G, Mehmel HC. Ventricular fibrillation due to long QT syndrome probably caused by clindamycin. Am J Cardiol 1999;83:813-815, A11.
185. Daleau P, Lessard E, Groleau MF, Turgeon J. Erythromycin blocks the rapid component of the delayed rectifier potassium current and lengthens repolarization of guinea pig ventricular myocytes. Circulation 1995;91:3010-3016.
186. Antzelevitch C, Sun ZQ, Zhang ZQ, Yan GX. Cellular and ionic mechanisms underlying erythromycin-induced long QT intervals and torsades de pointes. J Am Coll Cardiol 1996;28:1836-1848.
187. Dorsey ST, Biblo LA. Prolonged QT interval and torsades de pointes caused by the combination of fluconazole and amitriptyline. Am J Emerg Med 2000;18:227-229.
188. Wassmann S, Nickenig G, Bohm M. Long QT syndrome and torsades de pointes in a patient receiving fluconazole. Ann Intern Med 1999;131:797.
189. Tholakanahalli VN, Potti A, Hanley JF, Merliss AD. Fluconazole-induced torsades de pointes. Ann Pharmacother 2001;35:432-434.
190. Anderson ME, Mazur A, Yang T, Roden DM. Potassium current antagonist properties and proarrhythmic consequences of quinolone antibiotics. J Pharmacol Exp Ther 2001;296:806-810.
191. Dumaine R, Roy ML, Brown AM. Blockade of HERG and Kv1.5 by ketoconazole. J Pharmacol Exp Ther 1998;286:727-735.
192. Girgis I, Gualberti J, Langan L, et al. A prospective study of the effect of I.V. pentamidine therapy on ventricular arrhythmias and QTc prolongation in HIV-infected patients. Chest 1997;112:646-653.
193. Stramba-Badiale M, Nador F, Porta N, et al. QT interval prolongation and risk of life-threatening arrhythmias during toxoplasmosis prophylaxis with spiramycin in neonates. Am Heart J 1997;133: 108-111.
194. Lopez JA, Harold JG, Rosenthal MC, et al. QT prolongation and torsades de pointes after administration of trimethoprim-sulfamethoxazole. Am J Cardiol 1987;59:376-377.
195. Wiener I, Rubin DA, Martinez E, et al. QT prolongation and paroxysmal ventricular tachycardia occurring during fever following trimethoprim- sulfamethoxazole administration. Mt Sinai J Med 1981; 48:53-55.
196. Drolet B, Khalifa M, Daleau P, et al. Block of the rapid component of the delayed rectifier potassium current by the prokinetic agent cisapride underlies drug-related lengthening of the QT interval. Circulation 1998;97:204-210.
197. Mohammad S, Zhou Z, Gong Q, January CT. Blockage of the HERG human cardiac K+ channel by the gastrointestinal prokinetic agent cisapride. Am J Physiol 1997;273:H2534-H2538.
198. Rampe D, Roy ML, Dennis A, Brown AM. A mechanism for the proarrhythmic effects of cisapride (Propulsid): High affinity blockade of the human cardiac potassium channel HERG. FEBS Lett 1997; 417:28-32.
199. Scott MK, Kim MA, Kraus MA, et al. Effect of cisapride on QT interval in patients with end-stage renal disease. Am J Cardiol 2000;86:873-875.
200. Drolet B, Rousseau G, Daleau P, et al. Domperidone should not be considered a no-risk alternative to cisapride in the treatment of gastrointestinal motility disorders. Circulation 2000;102:1883-1885.
201. Chou CC, Wu D. Torsades de pointes induced by metoclopramide in an elderly woman with preexisting complete left bundle branch block. Chang Gung Med J 2001;24:805-809.
202. Baguley WA, Hay WT, Mackie KP, et al. Cardiac dysrhythmias associated with the intravenous administration of ondansetron and metoclopramide. Anesth Analg 1997;84:1380-1381.
203. De Lorenzi FG, Bridal TR, Spinelli W. Block of the delayed rectifier current (IK) by the 5-HT3 antagonists ondansetron and granisetron in feline ventricular myocytes. Br J Pharmacol 1994;113:527-535.
204. Kuryshev YA, Brown AM, Wang L, et al. Interactions of the 5-hydroxytryptamine 3 antagonist class of antiemetic drugs with human cardiac ion channels. J Pharmacol Exp Ther 2000;295:614-620.
205. Jo SH, Youm JB, Lee CO, et al. Blockade of the HERG human cardiac K(+) channel by the antidepressant drug amitriptyline. Br J Pharmacol 2000;129:1474-1480.
206. Teschemacher AG, Seward EP, Hancox JC, Witchel HJ. Inhibition of the current of heterologously expressed HERG potassium channels by imipramine and amitriptyline. Br J Pharmacol 1999;128: 479-485.
207. Leonard HL, Meyer MC, Swedo SE, et al. Electrocardiographic changes during desipramine and clomipramine treatment in children and adolescents. J Am Acad Child Adolesc Psychiatry 1995;34:1460-1468.
208. Gury C, Canceil O, Iaria P. Antipsychotic drugs and cardiovascular safety: Current studies of prolonged QT interval and risk of ventricular arrhythmia. Encephale 2000;26:62-72 (in French).
209. Ng AS, Johan A, Chia BL, Nadarajah K. Chlorpromazine induced T wave and QT alternans - A case report and review. Singapore Med J 1982;23:110-113.
210. Alter P, Tontsch D, Grimm W. Doxepin-induced torsades de pointes tachycardia. Ann Intern Med 2001;135:384-385.
211. Strasberg B, Coelho A, Welch W, et al. Doxepin induced torsades de pointes. Pacing Clin Electrophysiol 1982;5:873-877.
212. Buckley NA, Sanders P. Cardiovascular adverse effects of antipsychotic drugs. Drug Saf 2000;23:215-228.
213. Drolet B, Zhang S, Deschenes D, et al. Droperidol lengthens cardiac repolarization due to block of the rapid component of the delayed rectifier potassium current. J Cardiovasc Electrophysiol 1999; 10:1597-1604.
214. Lherm T, Lottin F, Larbi D, et al. Torsades de pointes after poisoning with fluoxetine alone. Presse Med 2000;29:306-307 (in French).
215. Thomas D, Gut B, Wendt-Nordahl G, Kiehn J. The antidepressant drug fluoxetine is an inhibitor of human ether-a-go-go-related gene (HERG) potassium channels. J Pharmacol Exp Ther 2002;300: 543-548.
216. Suessbrich H, Schonherr R, Heinemann SH, et al. The inhibitory effect of the antipsychotic drug haloperidol on HERG potassium channels expressed in Xenopus oocytes. Br J Pharmacol 1997;120: 968-974.
217. Rampe D, Murawsky MK, Grau J, Lewis EW. The antipsychotic agent sertindole is a high affinity antagonist of the human cardiac potassium channel HERG. J Pharmacol Exp Ther 1998;286:788-793.
218. Schmeling WT, Warltier DC, McDonald DJ, et al. Prolongation of the QT interval by enflurane, isoflurane, and halothane in humans. Anesth Analg 1991;72:137-144.
219. Kleinsasser A, Loeckinger A, Lindner KH, et al. Reversing sevoflurane-associated Q-Tc prolongation by changing to propofol. Anaesthesia 2001;56:248-250.
220. Ferreira S, Crumb WJ Jr, Carlton CG, Clarkson CW. Effects of cocaine and its major metabolites on the HERG-encoded potassium channel. J Pharmacol Exp Ther 2001;299:220-226.
221. O'Leary ME. Inhibition of human ether-a-go-go potassium channels by cocaine. Mol Pharmacol 2001;59:269-277.
222. Zhang S, Rajamani S, Chen Y, et al. Cocaine blocks HERG, but not KvLQT1+minK, potassium channels. Mol Pharmacol 2001; 59:1069-1076.
223. Rosati B, Rocchetti M, Zaza A, Wanke E. Sulfonylureas blockade of neural and cardiac HERG channels. FEBS Lett 1998;440: 125-130.
224. Ikeda T. QT prolongation in type 2 diabetes mellitus treated with glibenclamide. Diabetes Metab 1994;20:565-567.
225. Turgeon J, Daleau P, Bennett PB, et al. Block of IKs, the slow component of the delayed rectifier K+ current, by the diuretic agent indapamide in guinea pig myocytes. Circ Res 1994;75:879-886.
226. Fiset C, Drolet B, Hamelin BA, Turgeon J. Block of IKs by the diuretic agent indapamide modulates cardiac electrophysiological effects of the class III antiarrhythmic drug dl-sotalol. J Pharmacol Exp Ther 1997;283:148-156.
227. Geelen P, Drolet B, Rail J, et al. Sildenafil (Viagra) prolongs cardiac repolarization by blocking the rapid component of the delayed rectifier potassium current. Circulation 2000;102:275-277.
228. Liu XK, Katchman A, Ebert SN, Woosley RL. The antiestrogen tamoxifen blocks the delayed rectifier potassium current, IKr, in rabbit ventricular myocytes. J Pharmacol Exp Ther 1998;287:877-883.
229. Inoue H, Sugimoto T. Torsades de pointes and ventricular fibrillation in a canine model of quinidine-induced QT prolongation. Ann N Y Acad Sci 1992;644:93-102.
230. Gras J, Llenas J. Effects of H1 antihistamines on animal models of QTc prolongation. Drug Saf 1999;21(Suppl 1):39-44; discussion, 81-87.
231. Rubart M, Pressler ML, Pride HP, Zipes DP. Electrophysiological mechanisms in a canine model of erythromycin-associated long QT syndrome. Circulation 1993;88:1832-1844.
232. Chiba K, Sugiyama A, Satoh Y, et al. Proarrhythmic effects of fluoroquinolone antibacterial agents: In vivo effects as physiologic substrate for torsades. Toxicol Appl Pharmacol 2000;169:8-16.
233. Grissmer S, Nguyen AN, Aiyar J, et al. Pharmacological characterization of five cloned voltage-gated K+ channels, types Kv1.1, 1.2, 1.3, 1.5, and 3.1, stably expressed in mammalian cell lines. Mol Pharmacol 1994;45:1227-1234.
234. Snyders DJ, Tamkun MM, Bennett PB. A rapidly activating and slowly inactivating potassium channel cloned from human heart. Functional analysis after stable mammalian cell culture expression. J Gen Physiol 1993;101:513-543.